as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹276.9
Change
+11.25 (4.23%)
Open
₹264.5
Prev. Close
₹265.65
Day High
₹279.0
Day Low
₹260.5
Volume Analysis
Traded
368,055
Delivered
159,821
Delivery %
43.42%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (4)
- •Low return on equity (-81.5%)
- •Promoter holding is falling
- •Below-average fundamentals quality score (34/100)
- •Low operating margin (-4367.0%)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹302.26 | ₹290.63 | ₹283.76 | ₹272.13 | ₹265.26 | ₹253.63 | ₹246.76 |
| Fibonacci | ₹290.63 | ₹283.56 | ₹279.2 | ₹272.13 | ₹265.06 | ₹260.7 | ₹253.63 |
| Camarilla | ₹281.99 | ₹280.29 | ₹278.6 | ₹272.13 | ₹275.2 | ₹273.51 | ₹271.81 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+68.13%
1 Week
-1.69%
1 Month
-0.63%
3 Months
-25.79%
6 Months
+4.31%
1 Year
+56.37%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
-47.54%
Net margin -4244.44% × asset turnover 0.01x × equity multiplier 1.12x
Company Overview
Sector
Healthcare
Market Cap
₹7,850 Cr
ROE
-81.5%
Book Value
₹16.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Suven Life Sciences Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 34/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-81.5%); promoter holding is falling.
TopFund Score — Fundamentals Quality
34/100 — WeakData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- −Stock is trading at 17.3 times its book value
- −Company has low interest coverage ratio.
- −Promoter holding has decreased over last quarter: -4.61%
- −The company has delivered a poor sales growth of -12.0% over past five years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Suven Life Sciences will present seven CNS pipeline posters at Neuroscience 2026 in Washington DC, November 14–18.
Crisil report for Q2 FY27 notes 10% deviation approved, with Rs 53,763.36 lakh utilized under preferential issue.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3 | 2 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 | 1 |
| Expenses + | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 | 106 | 52 | 136 | 112 |
| Operating Profit | -24 | -46 | -30 | -31 | -52 | -39 | -44 | -51 | -80 | -103 | -51 | -132 | -111 |
| OPM % | -768.0% | -1,885.0% | -1,267.0% | -3,024.0% | -2,032.0% | -2,435.0% | -2,981.0% | -2,714.0% | -8,671.0% | -3,678.0% | -3,331.0% | -3,711.0% | -9,242.0% |
| Other Income + | 13 | 6 | 4 | 4 | 4 | 2 | 1 | 1 | 4 | 3 | 7 | 8 | 7 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Profit before tax | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 | -107 |
| Tax % | 0.0% | 0.0% | -4.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Profit + | -13 | -42 | -27 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 | -107 |
| EPS in Rs | -1 | -2 | -1 | -1 | -2 | -2 | -2 | -2 | -3 | -4 | -2 | -5 | -4 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | -30 | -18 | -8 | -73 | -16 | -34 | -38 | 85 | -64 | 75 | 3 | 91 | 30 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 521 | 499 | 543 | 625 | 286 | 13 | 13 | 12 | 14 | 12 | 7 | 7 | 9 |
| Expenses + | 361 | 398 | 414 | 427 | 300 | 128 | 93 | 134 | 139 | 140 | 172 | 291 | 406 |
| Operating Profit | 159 | 102 | 129 | 198 | -14 | -116 | -80 | -122 | -126 | -128 | -166 | -284 | -397 |
| OPM % | 31.0% | 20.0% | 24.0% | 32.0% | -5.0% | -917.0% | -593.0% | -1,032.0% | -929.0% | -1,094.0% | -2,487.0% | -3,999.0% | -4,367.0% |
| Other Income + | 9 | 19 | 21 | 23 | 27 | 14 | 8 | 5 | 14 | 29 | 11 | 14 | 24 |
| Interest | 5 | 6 | 6 | 5 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 12 | 18 | 21 | 21 | 11 | 4 | 4 | 4 | 7 | 6 | 6 | 6 | 7 |
| Profit before tax | 152 | 98 | 123 | 196 | 0 | -106 | -77 | -122 | -118 | -106 | -161 | -276 | -382 |
| Tax % | 28.0% | 26.0% | 29.0% | 37.0% | 15,038.0% | -11.0% | -7.0% | 0.0% | 0.0% | -1.0% | 0.0% | 0.0% | — |
| Net Profit + | 109 | 72 | 87 | 124 | -24 | -94 | -72 | -122 | -118 | -105 | -161 | -276 | -382 |
| EPS in Rs | 8 | 5 | 6 | 9 | -2 | -7 | -5 | -8 | -5 | -5 | -7 | -10 | -15 |
| Dividend Payout % | 7.0% | 35.0% | 15.0% | 15.0% | -80.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | — | -4 | 9 | 15 | -54 | -96 | 7 | -12 | 14 | -14 | -43 | 7 | 55 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 547 | 583 | 654 | 755 | 226 | 131 | 95 | 82 | 354 | 248 | 88 | 565 | 425 |
| Borrowings + | 109 | 83 | 71 | 34 | 3 | 6 | 5 | 3 | 2 | 1 | 0 | 17 | 16 |
| Other Liabilities + | 105 | 74 | 78 | 118 | 62 | 33 | 16 | 9 | 12 | 14 | 25 | 16 | 37 |
| Total Liabilities | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 624 | 506 |
| Fixed Assets + | 172 | 305 | 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 | 60 | 73 | 115 |
| CWIP | 107 | 7 | 10 | 25 | 0 | 0 | 5 | 4 | 0 | 0 | 0 | 4 | 4 |
| Investments | 0 | 0 | 301 | 279 | 223 | 0 | 0 | 45 | 46 | 76 | 22 | 181 | 14 |
| Other Assets + | 494 | 439 | 199 | 308 | 58 | 157 | 103 | 22 | 305 | 181 | 53 | 367 | 374 |
| Total Assets | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 624 | 506 |
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 | 22 | 22 | 22 | 26 | 28 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 143 | 68 | 109 | 70 | -53 | -135 | -96 | -128 | -116 | -115 | -155 | -300 |
| Cash from Investing Activity + | -110 | -39 | -311 | -1 | 30 | 146 | 56 | -22 | -248 | 94 | 155 | -462 |
| Cash from Financing Activity + | 179 | -68 | -30 | -52 | 5 | 3 | 35 | 146 | 396 | -1 | -1 | 757 |
| Net Cash Flow | 212 | -39 | -232 | 17 | -18 | 14 | -5 | -4 | 32 | -22 | -1 | -5 |
| Free Cash Flow | 25 | 10 | 79 | 28 | -92 | -137 | -102 | -147 | -119 | -113 | -193 | -305 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 113 | 93 | 111 | 57 | 262 | 114 | 119 | 104 | 91 | 95 | 93 | 106 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 29.88% | 28.91% | 28.21% | 28.34% | 28.35% | 29.47% | 29.12% | 28.07% | 28.18% | 24.32% | 26.42% | 31.89% |
| Promoters | 69.56% | 69.56% | 70.26% | 70.26% | 70.26% | 70.26% | 70.26% | 67.36% | 67.36% | 70.15% | 70.08% | 65.47% |
| FII | 0.54% | 0.46% | 0.45% | 0.33% | 0.34% | 0.25% | 0.58% | 1.17% | 1.07% | 0.91% | 0.56% | 0.45% |
| DII | 0.01% | 1.05% | 1.05% | 1.05% | 1.05% | 0.01% | 0.03% | 3.39% | 3.39% | 4.62% | 2.93% | 2.17% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Suven Life Sciences Ltd (this stock) | 7,850 | — | 17.38 | -81.5% |
| Thyrocare Tech Ltd | 7,940 | 45.3 | 14.31 | 28.4% |
| Sanofi India Limited | 7,603 | 17.2 | 8.83 | 47.1% |
| Healthcare Glob. Ent. Ltd | 8,562 | 216.0 | 6.36 | 2.54% |
| Kovai Medical Center & Ho | 7,108 | 123.0 | 24.58 | 22.2% |
| Bliss Gvs Pharma Ltd | 7,075 | 43.5 | 5.5 | 11.8% |
| Sun Pharma Adv.res.co.ltd | 6,680 | 4.05 | 4.64 | 279.0% |
Which Mutual Funds Hold Suven Life Sciences Ltd?
Frequently Asked Questions about Suven Life Sciences Ltd
Suven Life Sciences Ltd (SUVEN) closed at ₹276.9 on NSE on 19 November 2026, up 11.25 (4.23%) from the previous close.
Suven Life Sciences Ltd trades on the NSE (National Stock Exchange of India) under the symbol SUVEN.
Suven Life Sciences Ltd has a dividend yield of 0.0%.
Suven Life Sciences Ltd's 52-week high is ₹403.0 and its 52-week low is ₹124.0.
Suven Life Sciences Ltd has a market capitalisation of ₹7,850 crore.
Suven Life Sciences Ltd has a TopFund Quality Score of 34/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Suven Life Sciences Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.